Coherus Oncology announces deal with J&J

California, USA-based Coherus Oncology (Nasdaq: CHRS) has entered into a clinical supply agreement with JUS healthcare giant Johnson & Johnson (NYSE: JNJ) to evaluate tagmokitug (CHS-114), Coherus Oncology’s investigational anti-CCR8 cytolytic monoclonal antibody, in combination with pasritamig, a T-cell engaging bispecific antibody, in a Phase Ib clinical study in patients with metastatic castration-resistant prostate cancer (mCRPC).

“This agreement is representative of our strategy to accelerate development of our pipeline through partnerships and differentiated combinations,” said Denny Lanfear, chairman and chief executive at Coherus, previously known as Coherus Biosciences, adding: “We continue to advance our strategic vision to build a portfolio of first-in-class and best-in-class therapies designed to deliver a step change in survival for patients with difficult-to-treat cancers.”

Under the terms of the clinical supply agreement, J&J will provide pasritamig to Coherus, who will be the sponsor of the Phase Ib clinical trial. The companies each retain all commercial rights to their respective compounds, including as monotherapy or as combination treatments. No financial terms were disclosed.